FTC clears Novartis/Alcon with conditions

Health-care company Novartis has agreed to sell off a cataracts drug to a third party to ease the US Federal Trade Commission’s concerns about its merger with eye care rival and Texas-based Alcon.

Purchase an approved for publication custom PDF below.

An official PDF provides excellent marketing opportunities, enabling you to post the article online, make reprints and distribute under the GCR brand.

• £100 (GBP)
Add Amount: 1 2 3 4 5 6 7 8 9 10
• Add to Basket